GlassScriptPhysician profile
Kevin Michael May
NPI 1386767713
$1,700.53
in general payments reported to CMS, 2019-2025
18 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $15.99 · 2021: $226 · 2022: $154 · 2023: $179 · 2024: $326 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $412.45 | 2019-2024 | Clareon, Argos |
| Tg Therapeutics, INC. | $263.48 | 2025 | |
| Alexion Pharmaceuticals, INC. | $248.26 | 2025 | Ultomiris |
| Abbvie INC. | $177.95 | 2022-2025 | |
| Glaukos Corporation | $171.83 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Rxsight INC | $78.20 | 2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Horizon Therapeutics Plc | $60.20 | 2021 | |
| Allergan, INC. | $50.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.99 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $36.10 | 2021 | |
| Omeros Corporation | $29.20 | 2021 | |
| Astellas Pharma US INC | $27.32 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $24.14 | 2025 | Vyzulta |
| Biotissue Holdings INC. | $23.96 | 2022 | |
| Oyster Point Pharma, INC. | $19.29 | 2025 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $18.26 | 2025 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Ocular Therapeutix, INC. | $12.47 | 2021 | |
| Travere Therapeutics, INC. | $2.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.